Management of Neuromuscular Blocking Agents and Their Antagonism

Recruiting

• Conditions: Neuromuscular Blocking Agents; Neuromuscular Monitoring
• Interventions: Drug: Neuromuscular Blocking Agent

• Registration Number: NCT06238219
• Lead Sponsor: Erasme University Hospital

Brief Summary

Neuromuscular blocking agents (NMBA) are commonly used in clinical practice during general anesthesia to facilitate induction, intubation and surgery. Some studies have shown that their use can be deleterious if not codified. Recent recommendations concerning their use and antagonization were published in 2023.

Research hypothesis:

Using a single-center, retrospective practice study, we aim to analyze whether the 2023 ASA and ESAIC recommendations are being implemented regarding the use of neuromuscular blocking agents.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-01-23
• Study First Submitted QC: 2024-02-01
• Study First Posted: 2024-02-02
• Status Verified: 2024-04
• Study Start: 2024-04-17
• Last Update Submitted: 2024-04-18
• Last Update Posted: 2024-04-19
• Primary Completion: 2024-11-30
• Study Completion: 2024-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 3000

Inclusion Criteria

• All patients undergoing surgery with use of neuromuscular blocking agents at our institution

Exclusion Criteria

• Incomplete electronic anesthesia record

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
NMBA cohort	Neuromuscular Blocking Agent	Patients undergoing surgery under general anesthesia with use of neuromuscular blocking agents

Primary Outcome Measures

Name	Time	Method
Adherence to ASA and ESAIC guidelines for the use and monitoring of neuromuscular bocking agents (%)	10 hours	Train of four (TOF) ratio and TOF-count, as well as post-tetanic count (PTC) will be extracted from the electronic anesthesia record together with the type, dosage and timing of neuromuscular blocking agents. At intubation, antagonisation and extubation, the use of monitoring, the correct dose for antagonising agents (neostigmine or sugammadex) will be recorded. Concordance with current guidelines from ASA (American society of anaesthesiologists) and ESAIC (European society of anaesthesia and intensive care) will be analysed with a Chi-square test (observed versus expected). The % of adherence to the guidelines will be reported.

Trial Locations

Locations (1)

Hôpital Universitaire de Bruxelles - Hôpital erasme; 🇧🇪 Brussels, Belgium